Regulation of Vein Graft Hyperplasia by Survivin, an Inhibitor of Apoptosis Protein

OBJECTIVE—Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought to investigate the role of SVV in vein graft hyperplasia. METHODS AND RESULTS—Adenoviral constructs expressing a dominant-negative (AdT34A)...

Full description

Saved in:
Bibliographic Details
Published inArteriosclerosis, thrombosis, and vascular biology Vol. 25; no. 10; pp. 2081 - 2087
Main Authors Wang, Grace J, Sui, Xin Xin, Simosa, Hector F, Jain, Mukesh K, Altieri, Dario C, Conte, Michael S
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Heart Association, Inc 01.10.2005
Hagerstown, MD Lippincott
Subjects
Online AccessGet full text

Cover

Loading…
Abstract OBJECTIVE—Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought to investigate the role of SVV in vein graft hyperplasia. METHODS AND RESULTS—Adenoviral constructs expressing a dominant-negative (AdT34A) and wild-type (AdWT) SVV were used. Proliferation and apoptosis were assayed on endothelial cells (ECs) and smooth muscle cells (SMCs) from human saphenous vein. A rabbit carotid interposition vein graft model (N=31) was used, with adventitial gene transfer of SVV constructs. In vitro, overexpression of SVV was associated with protection from cytokine-induced apoptosis in ECs and SMCs; conversely, AdT34A directly induced apoptosis in these cells. SMC proliferation was increased by AdWT infection, whereas AdT34A reduced proliferation; both effects were serum-dependent. Expression of platelet-derived growth factor (PDGF) in SMCs was regulated by functional SVV expression in analogous fashion. In vivo, proliferation and apoptosis (7 days), as well as wall thickness (30 days), were modified by adenoviral-mediated SVV expression. Adventitial angiogenesis was regulated by the SVV-expressing constructs in a fashion parallel to wall thickness changes. CONCLUSIONS—SVV is a critical regulator of multiple processes, including proliferation, apoptosis, and angiogenesis, that determine the remodeling response of vein grafts following arterialization.
AbstractList OBJECTIVE: Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought to investigate the role of SVV in vein graft hyperplasia. METHODS AND RESULTS: Adenoviral constructs expressing a dominant-negative (AdT34A) and wild-type (AdWT) SVV were used. Proliferation and apoptosis were assayed on endothelial cells (ECs) and smooth muscle cells (SMCs) from human saphenous vein. A rabbit carotid interposition vein graft model (N=31) was used, with adventitial gene transfer of SVV constructs. In vitro, overexpression of SVV was associated with protection from cytokine-induced apoptosis in ECs and SMCs; conversely, AdT34A directly induced apoptosis in these cells. SMC proliferation was increased by AdWT infection, whereas AdT34A reduced proliferation; both effects were serum-dependent. Expression of platelet-derived growth factor (PDGF) in SMCs was regulated by functional SVV expression in analogous fashion. In vivo, proliferation and apoptosis (7 days), as well as wall thickness (30 days), were modified by adenoviral-mediated SVV expression. Adventitial angiogenesis was regulated by the SVV-expressing constructs in a fashion parallel to wall thickness changes. CONCLUSIONS: SVV is a critical regulator of multiple processes, including proliferation, apoptosis, and angiogenesis, that determine the remodeling response of vein grafts following arterialization.
OBJECTIVESurvivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought to investigate the role of SVV in vein graft hyperplasia.METHODS AND RESULTSAdenoviral constructs expressing a dominant-negative (AdT34A) and wild-type (AdWT) SVV were used. Proliferation and apoptosis were assayed on endothelial cells (ECs) and smooth muscle cells (SMCs) from human saphenous vein. A rabbit carotid interposition vein graft model (N=31) was used, with adventitial gene transfer of SVV constructs. In vitro, overexpression of SVV was associated with protection from cytokine-induced apoptosis in ECs and SMCs; conversely, AdT34A directly induced apoptosis in these cells. SMC proliferation was increased by AdWT infection, whereas AdT34A reduced proliferation; both effects were serum-dependent. Expression of platelet-derived growth factor (PDGF) in SMCs was regulated by functional SVV expression in analogous fashion. In vivo, proliferation and apoptosis (7 days), as well as wall thickness (30 days), were modified by adenoviral-mediated SVV expression. Adventitial angiogenesis was regulated by the SVV-expressing constructs in a fashion parallel to wall thickness changes.CONCLUSIONSSVV is a critical regulator of multiple processes, including proliferation, apoptosis, and angiogenesis, that determine the remodeling response of vein grafts following arterialization.
Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought to investigate the role of SVV in vein graft hyperplasia. Adenoviral constructs expressing a dominant-negative (AdT34A) and wild-type (AdWT) SVV were used. Proliferation and apoptosis were assayed on endothelial cells (ECs) and smooth muscle cells (SMCs) from human saphenous vein. A rabbit carotid interposition vein graft model (N=31) was used, with adventitial gene transfer of SVV constructs. In vitro, overexpression of SVV was associated with protection from cytokine-induced apoptosis in ECs and SMCs; conversely, AdT34A directly induced apoptosis in these cells. SMC proliferation was increased by AdWT infection, whereas AdT34A reduced proliferation; both effects were serum-dependent. Expression of platelet-derived growth factor (PDGF) in SMCs was regulated by functional SVV expression in analogous fashion. In vivo, proliferation and apoptosis (7 days), as well as wall thickness (30 days), were modified by adenoviral-mediated SVV expression. Adventitial angiogenesis was regulated by the SVV-expressing constructs in a fashion parallel to wall thickness changes. SVV is a critical regulator of multiple processes, including proliferation, apoptosis, and angiogenesis, that determine the remodeling response of vein grafts following arterialization.
Objective— Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought to investigate the role of SVV in vein graft hyperplasia. Methods and Results— Adenoviral constructs expressing a dominant-negative (AdT34A) and wild-type (AdWT) SVV were used. Proliferation and apoptosis were assayed on endothelial cells (ECs) and smooth muscle cells (SMCs) from human saphenous vein. A rabbit carotid interposition vein graft model (N=31) was used, with adventitial gene transfer of SVV constructs. In vitro, overexpression of SVV was associated with protection from cytokine-induced apoptosis in ECs and SMCs; conversely, AdT34A directly induced apoptosis in these cells. SMC proliferation was increased by AdWT infection, whereas AdT34A reduced proliferation; both effects were serum-dependent. Expression of platelet-derived growth factor (PDGF) in SMCs was regulated by functional SVV expression in analogous fashion. In vivo, proliferation and apoptosis (7 days), as well as wall thickness (30 days), were modified by adenoviral-mediated SVV expression. Adventitial angiogenesis was regulated by the SVV-expressing constructs in a fashion parallel to wall thickness changes. Conclusions— SVV is a critical regulator of multiple processes, including proliferation, apoptosis, and angiogenesis, that determine the remodeling response of vein grafts following arterialization. Vein graft remodeling is incompletely understood. Survivin (SVV) is a unique inhibitor of apoptosis protein that has been implicated in cancer and vascular injury. We investigated the role of SVV in vein graft healing and demonstrate that SVV regulates several processes, including proliferation, apoptosis, and angiogenesis, that determine vein graft remodeling
OBJECTIVE—Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought to investigate the role of SVV in vein graft hyperplasia. METHODS AND RESULTS—Adenoviral constructs expressing a dominant-negative (AdT34A) and wild-type (AdWT) SVV were used. Proliferation and apoptosis were assayed on endothelial cells (ECs) and smooth muscle cells (SMCs) from human saphenous vein. A rabbit carotid interposition vein graft model (N=31) was used, with adventitial gene transfer of SVV constructs. In vitro, overexpression of SVV was associated with protection from cytokine-induced apoptosis in ECs and SMCs; conversely, AdT34A directly induced apoptosis in these cells. SMC proliferation was increased by AdWT infection, whereas AdT34A reduced proliferation; both effects were serum-dependent. Expression of platelet-derived growth factor (PDGF) in SMCs was regulated by functional SVV expression in analogous fashion. In vivo, proliferation and apoptosis (7 days), as well as wall thickness (30 days), were modified by adenoviral-mediated SVV expression. Adventitial angiogenesis was regulated by the SVV-expressing constructs in a fashion parallel to wall thickness changes. CONCLUSIONS—SVV is a critical regulator of multiple processes, including proliferation, apoptosis, and angiogenesis, that determine the remodeling response of vein grafts following arterialization.
Author Wang, Grace J
Sui, Xin Xin
Simosa, Hector F
Altieri, Dario C
Conte, Michael S
Jain, Mukesh K
AuthorAffiliation From Vascular Surgery Research Laboratory (G.J.W., X.X.S., H.F.S., M.S.C.), Brigham and Womenʼs Hospital and Harvard Medical School, Boston, Mass; Cardiovascular Division (M.K.J.), Brigham and Womenʼs Hospital, Boston, Mass; Department of Cancer Biology and the Cancer Center (D.C.A.), University of Massachusetts Medical School, Worcester, Mass
AuthorAffiliation_xml – name: From Vascular Surgery Research Laboratory (G.J.W., X.X.S., H.F.S., M.S.C.), Brigham and Womenʼs Hospital and Harvard Medical School, Boston, Mass; Cardiovascular Division (M.K.J.), Brigham and Womenʼs Hospital, Boston, Mass; Department of Cancer Biology and the Cancer Center (D.C.A.), University of Massachusetts Medical School, Worcester, Mass
Author_xml – sequence: 1
  givenname: Grace
  surname: Wang
  middlename: J
  fullname: Wang, Grace J
  organization: From Vascular Surgery Research Laboratory (G.J.W., X.X.S., H.F.S., M.S.C.), Brigham and Womenʼs Hospital and Harvard Medical School, Boston, Mass; Cardiovascular Division (M.K.J.), Brigham and Womenʼs Hospital, Boston, Mass; Department of Cancer Biology and the Cancer Center (D.C.A.), University of Massachusetts Medical School, Worcester, Mass
– sequence: 2
  givenname: Xin
  surname: Sui
  middlename: Xin
  fullname: Sui, Xin Xin
– sequence: 3
  givenname: Hector
  surname: Simosa
  middlename: F
  fullname: Simosa, Hector F
– sequence: 4
  givenname: Mukesh
  surname: Jain
  middlename: K
  fullname: Jain, Mukesh K
– sequence: 5
  givenname: Dario
  surname: Altieri
  middlename: C
  fullname: Altieri, Dario C
– sequence: 6
  givenname: Michael
  surname: Conte
  middlename: S
  fullname: Conte, Michael S
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17173302$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16123317$$D View this record in MEDLINE/PubMed
BookMark eNpdkM1q3DAUhUVJyF_zCsUE2lXt6seS5e6G0CaBQEuTZiuuNVJHqUdyJDth3j5yZmAg2lwtvnPv4TtFBz54g9AFwRUhgnzDpFrcP1Q4PyKZlLwSgnBWSfiATgindVkLJg7yHzdtyUVNj9FpSo-ZrynFR-g4b6GMkeYE3f0x_6YeRhd8EWzxYJwvriLYsbjeDCYOPSQHRbcp7qb47J6d_1qAL278ynVuDHHOLIYwjCG5VPyOYcwLPqJDC30y57t5hv7-_HF_eV3e_rq6uVzclppjQUrBGom1MZYbI4W2uCOSQ91aroWwSyDUAKcAxLZcyg5wI2i75Ixr3jXaaHaGvmz3DjE8TSaNau2SNn0P3oQpKSFFXVPWZPDiHfgYpuhzN0WzEtligjP0fQvpGFKKxqohujXEjSJYzd4VJip7V3vv6s27kpDDn3YXpm5tlvvoTnQGPu8ASBp6G8Frl_ZckxmGaebqLfcS-tHE9L-fXkxUKwP9uJpP10xgXlKMOZmLlHMZwl4B_Z-crA
CODEN ATVBFA
CitedBy_id crossref_primary_10_1093_eurjhf_hfp135
crossref_primary_10_1096_fj_12_225615
crossref_primary_10_1182_blood_2006_06_028068
crossref_primary_10_1517_14656566_8_7_901
crossref_primary_10_3109_13880209_2014_884605
crossref_primary_10_1007_s10237_010_0224_8
crossref_primary_10_2353_ajpath_2010_091082
crossref_primary_10_1002_jcp_22676
crossref_primary_10_1111_acel_12844
crossref_primary_10_1586_14779072_6_5_641
crossref_primary_10_1063_5_0157549
crossref_primary_10_1186_s12967_017_1270_0
crossref_primary_10_1016_j_ajpath_2012_06_023
crossref_primary_10_1016_j_jvssci_2023_100126
crossref_primary_10_1016_j_jvs_2007_02_031
crossref_primary_10_1517_13543781003727099
crossref_primary_10_1016_j_jvs_2016_01_030
crossref_primary_10_1152_ajpheart_00637_2010
crossref_primary_10_1038_sj_mt_6300381
crossref_primary_10_1080_03079457_2012_663077
crossref_primary_10_1016_j_jacc_2009_04_006
crossref_primary_10_36660_abc_20200761
crossref_primary_10_1080_14779072_2019_1563483
crossref_primary_10_1016_j_mam_2017_07_005
crossref_primary_10_1016_j_mehy_2006_11_055
crossref_primary_10_1097_00029330_200811020_00005
crossref_primary_10_2310_6670_2007_00049
crossref_primary_10_1016_j_vph_2012_07_008
crossref_primary_10_1371_journal_pone_0113480
crossref_primary_10_1016_j_jvs_2018_05_206
crossref_primary_10_1016_j_mvr_2019_103905
crossref_primary_10_1016_j_surg_2006_04_004
crossref_primary_10_1007_s10557_007_6018_2
crossref_primary_10_1152_ajpheart_00089_2011
crossref_primary_10_1371_journal_pone_0264217
crossref_primary_10_1517_13543784_16_6_803
crossref_primary_10_1113_expphysiol_2009_050971
crossref_primary_10_1152_ajpheart_00079_2008
crossref_primary_10_1016_j_jvs_2009_02_242
Cites_doi 10.1161/circ.101.12.1362
10.1016/S0741-5214(96)70203-3
10.1016/0022-4804(91)90029-L
10.1161/atvb.16.1.19
10.1182/blood-2003-05-1756
10.1161/01.cir.0000145138.25577.f1
10.1172/JCI200422222
10.1161/01.res.0000097864.24725.60
10.1016/S0735-1097(97)00076-4
10.1073/pnas.89.22.10984
10.1038/nrc968
10.1038/sj.onc.1205353
10.1073/pnas.0406665101
10.1074/jbc.M309479200
10.1016/S1072-7515(00)00320-3
10.1016/S0002-9440(10)64131-4
10.1016/S0960-9822(00)00769-7
10.1161/01.atv.0000116865.98067.31
10.1093/emboj/17.8.2215
10.1074/jbc.M003670200
10.1016/j.bbrc.2004.08.149
10.1016/j.jvs.2005.01.006
10.1172/JCI200112983
10.1038/sj.onc.1207113
10.1038/nm750
10.1161/circ.95.12.2684
10.1074/jbc.M106643200
10.1161/circ.94.7.1655
10.1152/ajpheart.00760.2003
10.1177/1358836X0000500207
ContentType Journal Article
Copyright 2005 American Heart Association, Inc.
2005 INIST-CNRS
Copyright American Heart Association, Inc. Oct 2005
Copyright_xml – notice: 2005 American Heart Association, Inc.
– notice: 2005 INIST-CNRS
– notice: Copyright American Heart Association, Inc. Oct 2005
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
K9.
7X8
DOI 10.1161/01.ATV.0000183885.66153.8a
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
MEDLINE
CrossRef

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4636
EndPage 2087
ExternalDocumentID 909089931
10_1161_01_ATV_0000183885_66153_8a
16123317
17173302
00043605-200510000-00011
Genre Research Support, U.S. Gov't, P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: CA90917
– fundername: NHLBI NIH HHS
  grantid: HL072952
– fundername: NHLBI NIH HHS
  grantid: 5T32-HL07734
– fundername: NHLBI NIH HHS
  grantid: K08 HL04189-01
– fundername: NCI NIH HHS
  grantid: CA78810
– fundername: NHLBI NIH HHS
  grantid: HL54131
GroupedDBID -
.Z2
01R
08R
0R
1J1
23N
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
55
5GY
5RE
5VS
71W
77Y
7O
7O~
AAAXR
AAMOA
AAMTA
AAPBV
AARTV
AAXQO
ABBUW
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFS
ACGOD
ACPRK
ACWDW
ACWRI
ACXNZ
ADACO
ADBBV
ADFPA
ADNKB
AE3
AENEX
AFFNX
AFUWQ
AHMBA
AHULI
AHVBC
AIJEX
AJIOK
AJNYG
AJYGW
ALMA_UNASSIGNED_HOLDINGS
AMJPA
ASCII
AWKKM
BAWUL
BOYCO
C1A
C45
CS3
DIK
DUNZO
E.X
E3Z
EBS
EJD
EX3
F2K
F2L
F2M
F2N
F5P
FL-
FRP
FW0
GJ
GX1
H0
H0~
H13
HZ
IKYAY
IN
IN~
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
LI0
N9A
N~7
N~B
N~M
O0-
O9-
OAG
OAH
OB2
OCUKA
ODA
OHASI
OK1
OL1
OLG
OLH
OLU
OLV
OLW
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWW
OWY
OXXIT
P-K
P2P
PQEST
PQQKQ
PZZ
RAH
RHF
RIG
RLZ
RSW
S4R
S4S
V2I
WOQ
WOW
X3V
X3W
X7M
Z2
ZA5
ZGI
---
.3C
.55
.GJ
0R~
AAGIX
AAHPQ
AAQKA
AASOK
AAUGY
ABASU
ABDIG
ABQRW
ACCJW
ACILI
ADGGA
AE6
AEETU
AFDTB
AGINI
AHJKT
AHOMT
AHRYX
AJNWD
AKALU
AKULP
ALMTX
AMKUR
AMNEI
AOHHW
AYCSE
BS7
DIWNM
EEVPB
FCALG
GNXGY
GQDEL
HZ~
IKREB
IPNFZ
IQODW
OJAPA
OWU
OWV
OWX
OWZ
T8P
TEORI
TR2
TSPGW
VVN
W3M
W8F
XXN
XYM
YFH
ZZMQN
AAAAV
AAIQE
AASCR
ABJNI
ABVCZ
ACXJB
ADHPY
AHQNM
AINUH
AJZMW
CGR
CUY
CVF
ECM
EIF
ERAAH
HLJTE
NPM
AAYXX
CITATION
K9.
7X8
ID FETCH-LOGICAL-c5061-63780ceef5ee86cf0b185a49f5c66fda12ea52aa1f9588ba07629d535c5b7cec3
ISSN 1079-5642
IngestDate Sat Aug 17 02:32:35 EDT 2024
Thu Aug 29 12:51:45 EDT 2024
Fri Aug 23 00:17:21 EDT 2024
Sat Sep 28 08:40:24 EDT 2024
Sun Oct 22 16:04:00 EDT 2023
Thu Aug 13 19:50:12 EDT 2020
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Vascular disease
Angiogenesis
survivin
proliferation
Hyperplasia
Atherosclerosis
Cardiovascular disease
intimal hyperplasia
Apoptosis
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c5061-63780ceef5ee86cf0b185a49f5c66fda12ea52aa1f9588ba07629d535c5b7cec3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ahajournals.org/doi/pdf/10.1161/01.ATV.0000183885.66153.8a
PMID 16123317
PQID 204289010
PQPubID 49288
PageCount 7
ParticipantIDs proquest_miscellaneous_68644237
proquest_journals_204289010
crossref_primary_10_1161_01_ATV_0000183885_66153_8a
pubmed_primary_16123317
pascalfrancis_primary_17173302
wolterskluwer_health_00043605-200510000-00011
ProviderPackageCode L-C
C45
7O~
AARTV
ADFPA
OLH
ASCII
OLG
AAMOA
ODA
ABZAD
ABBUW
JK3
ADNKB
JK8
H0~
1J1
OLV
OLU
JG8
OLW
OLZ
OLY
F2K
F2M
F2L
F2N
OHASI
AHVBC
AJNYG
FL-
KMI
K8S
OVLEI
AJIOK
OPUJH
V2I
S4R
S4S
4Q1
DUNZO
OAG
4Q2
OVDNE
4Q3
AMJPA
OAH
OVD
71W
AHULI
OB2
ACEWG
.Z2
N~7
IKYAY
OVIDH
AWKKM
40H
N~B
OUVQU
ORVUJ
X3V
X3W
ACDDN
ACWRI
BOYCO
AIJEX
AAXQO
AAMTA
AAAXR
E.X
OWW
OCUKA
OWY
01R
ACXNZ
OL1
ABXVJ
IN~
KD2
OXXIT
77Y
ACWDW
JF9
FW0
PublicationCentury 2000
PublicationDate 2005-October
PublicationDateYYYYMMDD 2005-10-01
PublicationDate_xml – month: 10
  year: 2005
  text: 2005-October
PublicationDecade 2000
PublicationPlace Philadelphia, PA
Hagerstown, MD
PublicationPlace_xml – name: Philadelphia, PA
– name: Hagerstown, MD
– name: United States
– name: Hagerstown
PublicationTitle Arteriosclerosis, thrombosis, and vascular biology
PublicationTitleAlternate Arterioscler Thromb Vasc Biol
PublicationYear 2005
Publisher American Heart Association, Inc
Lippincott
Publisher_xml – name: American Heart Association, Inc
– name: Lippincott
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_20_2
e_1_3_2_21_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_24_2
e_1_3_2_25_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_19_2
e_1_3_2_1_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_2_2
e_1_3_2_14_2
References_xml – ident: e_1_3_2_26_2
  doi: 10.1161/circ.101.12.1362
– ident: e_1_3_2_20_2
  doi: 10.1016/S0741-5214(96)70203-3
– ident: e_1_3_2_8_2
  doi: 10.1016/0022-4804(91)90029-L
– ident: e_1_3_2_14_2
  doi: 10.1161/atvb.16.1.19
– ident: e_1_3_2_28_2
  doi: 10.1182/blood-2003-05-1756
– ident: e_1_3_2_30_2
  doi: 10.1161/01.cir.0000145138.25577.f1
– ident: e_1_3_2_1_2
– ident: e_1_3_2_23_2
  doi: 10.1172/JCI200422222
– ident: e_1_3_2_4_2
  doi: 10.1161/01.res.0000097864.24725.60
– ident: e_1_3_2_10_2
  doi: 10.1016/S0735-1097(97)00076-4
– ident: e_1_3_2_12_2
– ident: e_1_3_2_11_2
  doi: 10.1073/pnas.89.22.10984
– ident: e_1_3_2_5_2
  doi: 10.1038/nrc968
– ident: e_1_3_2_19_2
  doi: 10.1038/sj.onc.1205353
– ident: e_1_3_2_24_2
  doi: 10.1073/pnas.0406665101
– ident: e_1_3_2_18_2
  doi: 10.1074/jbc.M309479200
– ident: e_1_3_2_31_2
  doi: 10.1016/S1072-7515(00)00320-3
– ident: e_1_3_2_15_2
  doi: 10.1016/S0002-9440(10)64131-4
– ident: e_1_3_2_16_2
  doi: 10.1016/S0960-9822(00)00769-7
– ident: e_1_3_2_2_2
  doi: 10.1161/01.atv.0000116865.98067.31
– ident: e_1_3_2_22_2
  doi: 10.1093/emboj/17.8.2215
– ident: e_1_3_2_21_2
  doi: 10.1074/jbc.M003670200
– ident: e_1_3_2_27_2
  doi: 10.1016/j.bbrc.2004.08.149
– ident: e_1_3_2_7_2
  doi: 10.1016/j.jvs.2005.01.006
– ident: e_1_3_2_9_2
  doi: 10.1172/JCI200112983
– ident: e_1_3_2_32_2
  doi: 10.1038/sj.onc.1207113
– ident: e_1_3_2_6_2
  doi: 10.1038/nm750
– ident: e_1_3_2_3_2
  doi: 10.1161/circ.95.12.2684
– ident: e_1_3_2_17_2
  doi: 10.1074/jbc.M106643200
– ident: e_1_3_2_25_2
  doi: 10.1161/circ.94.7.1655
– ident: e_1_3_2_13_2
  doi: 10.1152/ajpheart.00760.2003
– ident: e_1_3_2_29_2
  doi: 10.1177/1358836X0000500207
SSID ssj0004220
Score 2.0665624
Snippet OBJECTIVE—Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We...
Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought to...
Objective— Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We...
OBJECTIVE: Survivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We...
OBJECTIVESurvivin (SVV) is an inhibitor of apoptosis protein (IAP) that is upregulated in cancer and has recently been implicated in vascular injury. We sought...
SourceID proquest
crossref
pubmed
pascalfrancis
wolterskluwer
SourceType Aggregation Database
Index Database
Publisher
StartPage 2081
SubjectTerms Adenoviridae - genetics
Animals
Apoptosis - physiology
Atherosclerosis (general aspects, experimental research)
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Carotid Arteries - pathology
Carotid Arteries - surgery
Carotid Artery Diseases - metabolism
Carotid Artery Diseases - pathology
Carotid Artery Diseases - physiopathology
Cell Division - physiology
Cells, Cultured
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Endothelium, Vascular - cytology
Endothelium, Vascular - metabolism
Genetic Vectors
Graft Survival - physiology
Humans
Hyperplasia
Inhibitor of Apoptosis Proteins
Jugular Veins - pathology
Jugular Veins - transplantation
Medical sciences
Microtubule-Associated Proteins - genetics
Microtubule-Associated Proteins - metabolism
Muscle, Smooth, Vascular - cytology
Muscle, Smooth, Vascular - metabolism
Neoplasm Proteins - genetics
Neoplasm Proteins - metabolism
Neovascularization, Pathologic - metabolism
Neovascularization, Pathologic - pathology
Neovascularization, Pathologic - physiopathology
Platelet-Derived Growth Factor - metabolism
Rabbits
Saphenous Vein - cytology
Signal Transduction - physiology
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the heart
Survivin
Vascular surgery: aorta, extremities, vena cava. Surgery of the lymphatic vessels
Title Regulation of Vein Graft Hyperplasia by Survivin, an Inhibitor of Apoptosis Protein
URI http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00043605-200510000-00011
https://www.ncbi.nlm.nih.gov/pubmed/16123317
https://www.proquest.com/docview/204289010/abstract/
https://search.proquest.com/docview/68644237
Volume 25
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEkhHgTCiUHbiVLXnacY4WAqqhI0C3aW2QnDrsqTaLNbhHc-d_M2M5joZWAS7SbOE6UbzyeGc98JuSFTFgaU8q8pEhyL2aSeqmfFp4vJE8xDSPJMQ55_IEdnsZHczqfTH6OspY2aznNf1xaV_I_qMI5wBWrZP8B2b5TOAG_AV84AsJw_CuMP5mN5K3Nd6GW1f6XlSjX-wvwLleNrpBE-7LdgEK4MGwBAlMbF0sJI1kvEIimbtY10pJoygZLxN3z0iKVc93Cc1fYBjvAjRXOZfcP4-59NqtldBqC9EaRvFsJ0B6j9SedQTCHt50ve9k8AaFphZkJcSFhSDk-EubNjzdnql3YuGwXqKB9yhvMM1a5hrGHBGVj7WvKnjsp88e61Debufyp5FmgCxemB7PPmn8S1BLndMrQeJ1yMb4JAGvONfwBEs1EplD0N4rt7tI1cj1MUoo-_PuPI9L5MOz4aqHlq6sfjAy0tqstM-dWAziIr6XZKuUyXwbafKsxPaI909URIxtndofcts6Je2Ak7S6ZqOoeuXFs0y_uk5NB4Ny6dFHgXC1w7kjgXPnd7QTupSsqtxc3vKcXN9eK2wNy-vbN7PWhZ3fl8HIKxp_HooT7YFqVVCnO8tKXYPKJOC1pzlhZiCBUgoZCBGVKOZfCh-k2LWhEcyqTXOXRQ7JT1ZV6TFwVyrKkSUAFL-JcljxRNKQCffpCRLxwSNR9xKwx5CuZdlpZkPlBBihkAwqZRiHjwiF7W997uBUzTiI_dMhuB0BmR3ObhRg8wFwlhzzvr4KqxfUzUal602aMg_MA6sshjwxqQ88WdYd4WzBmppg50wvuDIZEqCdBy-YQBE-u7GmX3BzG0FOys15t1DMwf9dyTwvnL-8Zqjw
link.rule.ids 315,786,790,27957,27958
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Regulation+of+vein+graft+hyperplasia+by+survivin%2C+an+inhibitor+of+apoptosis+protein&rft.jtitle=Arteriosclerosis%2C+thrombosis%2C+and+vascular+biology&rft.au=Wang%2C+Grace+J&rft.au=Sui%2C+Xin+Xin&rft.au=Simosa%2C+Hector+F&rft.au=Jain%2C+Mukesh+K&rft.date=2005-10-01&rft.eissn=1524-4636&rft.volume=25&rft.issue=10&rft.spage=2081&rft_id=info:doi/10.1161%2F01.ATV.0000183885.66153.8a&rft_id=info%3Apmid%2F16123317&rft.externalDocID=16123317
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-5642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-5642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-5642&client=summon